Last reviewed · How we verify

QazCovid-in®-vaccine against COVID-19 — Competitive Intelligence Brief

QazCovid-in®-vaccine against COVID-19 (QazCovid-in®-vaccine against COVID-19) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Disease.

phase 3 Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

QazCovid-in®-vaccine against COVID-19 (QazCovid-in®-vaccine against COVID-19) — Research Institute for Biological Safety Problems. QazCovid-in stimulates an immune response to provide protection against COVID-19.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
QazCovid-in®-vaccine against COVID-19 TARGET QazCovid-in®-vaccine against COVID-19 Research Institute for Biological Safety Problems phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QazCovid-in®-vaccine against COVID-19 — Competitive Intelligence Brief. https://druglandscape.com/ci/qazcovid-in-vaccine-against-covid-19. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: